<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154635">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01803191</url>
  </required_header>
  <id_info>
    <org_study_id>BIPROST</org_study_id>
    <secondary_id>2012-001031-31</secondary_id>
    <nct_id>NCT01803191</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy</brief_title>
  <acronym>BIPROST</acronym>
  <official_title>Randomized Controlled Clinical Trial of Efficacy of Fosfomycin Versus Ciprofloxacin as Antibiotic Prophylaxis Prior to Ultrasound Guided Transrectal Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Universitario Santa Lucía</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Los Arcos del Mar Menor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is compare the incidence of symptomatic or asymptomatic
      bacteriuria after transrectal ultrasound guided prostate biopsy using a single dose of
      fosfomycin 3 g one hour before the biopsy compared to  observed with the use of a single
      dose of ciprofloxacin 500 mg 1 hour before biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transrectal ultrasound guided (TRUS) prostate biopsy is the procedure of choice for the
      diagnosis of prostate cancer. This technique is usually safe and well tolerated with a low
      incidence of serious complications. However, one of these complications, the bacterial
      infection can be complicated and cause urinary sepsis. The investigators have developed
      different regimens of antibiotic prophylaxis. Most of them include administering oral
      fluoroquinolones. In this area, approximately 40% of the strains of E. coli are resistant to
      ciprofloxacin (fluoroquinolone). Therefore, research is warranted alternative prophylactic
      approaches. Fosfomycin is an antibiotic ancient underused in recent decades that in recent
      years has been proposed as an alternative treatment for infections caused by
      multidrug-resistant microorganisms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Bacteriuria</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive urine culture(&gt;10000 ufc/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Tract Infection</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical symptoms (burning urination, urgent urination, urinary frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Systemic inflammatory response syndrome secondary to urinary tract infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathogens present in urine and antimicrobial resistance</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence of bacteria in the blood (blood culture positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematuria</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood in urine (Complication of transrectal ultrasound guided prostate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemospermia</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood in the semen (Complication of transrectal ultrasound guided prostate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rectal bleeding</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Loss of red blood through the anus(Complication of transrectal ultrasound guided prostate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary retention</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complication of transrectal ultrasound guided prostate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty for miction</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complication of transrectal ultrasound guided prostate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genitourinary infections associated to fever (&gt;38ºC)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fever &gt;38ºC with some of this symptoms: dysuria, polyuria or suprapubic ache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Fosfomycin 3 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unique oral dosis of ciprofloxacin 500 mg before biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin 3 g</intervention_name>
    <description>Unique oral dosis of fosfomycin 1 hour before biopsy</description>
    <arm_group_label>Fosfomycin 3 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 500 mg</intervention_name>
    <description>Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy</description>
    <arm_group_label>Ciprofloxacin 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Patients with prostate-specific antigen (PSA) values &gt;4 ng/ml or presenting either
             abnormality in rectal examination

          -  Patients who accept to participate in the study signing the consent informed form

        Exclusion Criteria:

          -  Allergy to anyone of the study drug

          -  Intolerance to anyone of the study drug

          -  Urinary infection with positive uroculture

          -  Clinical finds suggesting infections

          -  Antimicrobial treatment during the las 4 weeks

          -  Patients with vesicle catheter

          -  Patients in dialysis

          -  Patients in hemodialysis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro PL Lopez Cubillana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro PL López, MD</last_name>
    <phone>968369500</phone>
    <email>pedrolopezcubillana@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan JM Moreno, MD</last_name>
    <phone>968128600</phone>
    <email>jmorenoav@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Moreno Aviles, MD</last_name>
      <phone>968128600</phone>
      <email>jmorenoav@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Moreno Avilés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos García Espona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose M Cervell Ferrón, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Almudena Rodríguez Tardido, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Cao Avellaneda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenio Hita Rosino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Jimenez Penick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan M Soler Fernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Max Cachay Ayala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30150</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Muñoz Garcia</last_name>
      <phone>968 381290</phone>
      <email>maria.munoz@ffis.es</email>
    </contact>
    <investigator>
      <last_name>Pedro Lopez Cubillana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Martinez Pertusa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angel Guardiola Mas, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Prieto González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Gómez Gómez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Server Pastor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A García Hernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A Nicolas Torralba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Félix Escudero Bregante, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús I Tornero Ruiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariano Rigabert Montiel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro A López gonzález, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose C Ruiz Morcillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristobal Moreno alarcón, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edgar Olarte Barragán, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy P. Pinzón Navarrete, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Gutierrez Gutierrez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A Herrero Martinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan D Aviles Hernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Los Arcos del Mar Menor</name>
      <address>
        <city>San Javier</city>
        <state>Murcia</state>
        <zip>30739</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Guzmán Martinez-Valls, MD</last_name>
      <phone>968565030</phone>
      <email>pabloguzmanmv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Guzman Martínez Valls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Maluff Torres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatriz Honrubia Vilchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gloria Doñate Iñiguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transrectal ultrasound-guided prostate biopsy</keyword>
  <keyword>Bacteriuria</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>Prostate-Specific antigen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
